Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170035/S021

Bausch + Lomb Ultra (samfilcon A) Contact Lenses

Bausch and Lomb, Inc., · Decision date Sep 14, 2026

MEDTECHLEDGER EXPLANATIONP170035/S021

What did the FDA decide?

The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-14 for P170035/S021, a supplement to the approved application for Bausch + Lomb Ultra (samfilcon A) Contact Lenses. The applicant is Bausch and Lomb, Inc. The supplement reason is listed as a process change affecting a manufacturer, sterilizer, packager or supplier, and the device falls under the soft contact lens, extended wear category in the ophthalmic specialty, product code LPM.

The recorded scope is the expansion and relocation of the monomer mix manufacturing area at the applicant's Rochester, NY facility. This describes a manufacturing-site change within the existing application rather than a new approval of the lens system. The source record includes no supporting documents, so the review basis, any conditions on the decision, and whether the relocated area required separate inspection are not stated here and remain unknown.

FDA approval order statement

expansion and relocation of the monomer mix manufacturing area at Bausch + Lombs manufacturing facility located in Rochester, NY
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Sep 14, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P170035/S021
Regulatory pathway
PMA supplement
Product code
LPM
Decision code
OK30
Decision date
Sep 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

For the original device and its historical approval scope, see PMA P170035. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P170035 · Original PMA

    Bausch + Lomb Ultra (samfilcon A) Contact Lenses

  2. P170035/S021 received

    Application receipt date recorded by FDA.

  3. P170035/S021 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P170035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170035

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch and Lomb, Inc.,PMA approvalApr 30, 2018FDA

Explore the linked device profile

Other records with product code LPM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bausch and Lomb, Inc.,

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1400 N. Goodman St., Rochester, NY, 14609

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records